US Stock MarketDetailed Quotes
ELDN Eledon Pharmaceuticals
- 2.490
- -0.050-1.97%
Close Sep 27 16:00 ET
- 2.460
- -0.030-1.20%
Post 20:02 ET
98.74MMarket Cap-943P/E (TTM)
2.550High2.450Low41.46KVolume2.510Open2.540Pre Close103.59KTurnover0.14%Turnover RatioLossP/E (Static)39.66MShares3.34952wk High-11.64P/B71.94MFloat Cap1.07052wk Low--Dividend TTM28.89MShs Float4864.865Historical High--Div YieldTTM3.94%Amplitude1.070Historical Low2.498Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Eledon Pharmaceuticals Stock Forum
Eledon Announces Completion of Enrollment in Phase 2 Bestow Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.
The study involved 13 participants and demonstrated a consistent mean eGFR of 70.5 mL/min/1.73m² at all reported time points post-transpl...
NEWS
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
05/09/2024 - 04:00 AM
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will ...
Benzinga· 2 mins ago
Pull up Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), this company has made headlines with its announcement of securing an oversubscribed $50 million private placement. This strategic financial endeavor is not just a testament to the confidence that institutional and accredited healthcar...
Eledon Pharmaceuticals Announced A Private Investment Of Approximately $50M, With Sale Of 13.1M Shares At $2.37/Share And Pre-funded Warrants At $2.369/Underlying Share, Which Are Exercisable To Purchase 7.99M Shares
No comment yet